Clinical Trial Update: EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion [Phase 2]

View source ↗

Summary

Phase 2 trial of eplerenone to prevent recurrences of atrial fibrillation after cardioversion has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eplerenone (Inspra) (eplerenone)

Snippet

Sponsor: University Hospital, Saarland | Conditions: Atrial Fibrillation | Phase 2 | Status: TERMINATED